Related Experiment Videos

Variability of serum levels for three oral 8-methoxypsoralen brands

T Walther1, B Quednow, U F Haustein

  • 1Department of Dermatology, University of Leipzig, Germany.

Insights

This pilot study compared three 8-methoxypsoralen (8-MOP) preparations. Geroxalen soft gelatin capsules showed higher serum levels compared to Oxsoralen capsules and Mopsoralen tablets, suggesting formulation impacts bioavailability for PUVA therapy.

Area of Science:

  • Pharmacology
  • Dermatology
  • Drug Formulation

Background:

  • 8-methoxypsoralen (8-MOP) is crucial for PUVA therapy.
  • Understanding 8-MOP serum levels is vital for treatment efficacy.
  • Interindividual variability in drug absorption necessitates comparative studies.

Purpose of the Study:

  • To investigate and compare serum level patterns of three commercial 8-methoxypsoralen (8-MOP) preparations.
  • To assess the bioequivalence of different 8-MOP formulations.
  • To analyze interindividual variability in serum 8-MOP concentrations over time.

Main Methods:

  • Pilot study involving 9 patients.
  • Administration of 30 mg 8-MOP equivalent doses of three preparations: Geroxalen soft gelatin capsules, Oxsoralen hard gelatin capsules, and Mopsoralen tablets.
  • Serum level monitoring over 8 hours post-ingestion.
  • Analysis of Cmax and serum level ranges.

Main Results:

  • Geroxalen soft gelatin capsules yielded the highest average Cmax (120.1 ng.ml-1) at 0.5-1 hour.
  • Oxsoralen hard gelatin capsules and Mopsoralen tablets showed lower average Cmax values (82.3 and 81.3 ng.ml-1, respectively).
  • Significant interindividual variability in serum levels was observed across all preparations.

Conclusions:

  • Formulation significantly impacts 8-methoxypsoralen (8-MOP) pharmacokinetics.
  • Geroxalen soft gelatin capsules demonstrate potentially superior absorption compared to other tested formulations.
  • Serum level monitoring of 8-MOP may enhance the efficiency and effectiveness of PUVA therapy.

Related Concept Videos